Zenas BioPharma Files 8-K on Financials
Ticker: ZBIO · Form: 8-K · Filed: Feb 5, 2025 · CIK: 1953926
Sentiment: neutral
Topics: financial-condition, results-of-operations, disclosure
TL;DR
Zenas BioPharma dropped an 8-K detailing its financial condition and results of operations.
AI Summary
Zenas BioPharma, Inc. filed an 8-K on February 5, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 852 Winter Street, Suite 250, Waltham, MA.
Why It Matters
This 8-K filing provides investors with an update on Zenas BioPharma's financial performance and condition, which is crucial for evaluating the company's stability and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or material adverse events.
Key Players & Entities
- Zenas BioPharma, Inc. (company) — Registrant
- February 5, 2025 (date) — Date of earliest event reported
- 852 Winter Street, Suite 250 (location) — Principal executive offices address
- Waltham, MA (location) — Principal executive offices city and state
- 02451 (location) — Principal executive offices zip code
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Zenas BioPharma, Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on February 5, 2025.
Where are Zenas BioPharma, Inc.'s principal executive offices located?
Zenas BioPharma, Inc.'s principal executive offices are located at 852 Winter Street, Suite 250, Waltham, MA 02451.
What is the company's state of incorporation?
The company is incorporated in Delaware.
What is the Standard Industrial Classification code for Zenas BioPharma, Inc.?
The Standard Industrial Classification code for Zenas BioPharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 825 words · 3 min read · ~3 pages · Grade level 13.2 · Accepted 2025-02-05 07:17:09
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ZBIO The Nasdaq Global Se
- $350 million — short-term investments of approximately $350 million as of December 31, 2024. This amount is
Filing Documents
- tm255498d1_8k.htm (8-K) — 32KB
- tm255498d1_ex99-1.htm (EX-99.1) — 41KB
- tm255498d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-25-009368.txt ( ) — 261KB
- zbio-20250205.xsd (EX-101.SCH) — 3KB
- zbio-20250205_lab.xml (EX-101.LAB) — 33KB
- zbio-20250205_pre.xml (EX-101.PRE) — 22KB
- tm255498d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On February 5, 2025, Zenas BioPharma, Inc. (the "Company") issued a press release announcing its 2024 accomplishments and outlined its key business objectives for 2025. The Company also disclosed that it had a preliminary unaudited amount of cash, cash equivalents, and short-term investments of approximately $350 million as of December 31, 2024. This amount is preliminary and unaudited and is subject to completion of the Company's financial closing procedures. As a result, this amount may differ materially from the amount that will be reflected in the Company's consolidated financial statements for the year ended December 31, 2024. A copy of the press release disclosing this information is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated into this Item 2.02 by reference. The preliminary unaudited financial data included in this Current Report on Form 8-K has been prepared by, and is the responsibility of, the Company's management. Ernst & Young, LLP, the Company's auditor, has not audited, reviewed, examined, compiled, nor applied agreed-upon procedures with respect to the preliminary financial data. Accordingly, Ernst & Young, LLP does not express an opinion or any other form of assurance with respect thereto. The information contained in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements. Investors are cautioned not to place unduereliance on these forward-looking statements, includi
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on February 5, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ZENAS BIOPHARMA, INC. By: /s/ Jennifer Fox Name: Jennifer Fox Title: Chief Business Officer and Chief Financial Officer Date: February 5, 2025